Pre-made Murlentamab benchmark antibody ( Whole mAb, anti-AMHR2 therapeutic antibody, Anti-AMHR/MISR2/MISRII/MRII Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-359

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-359 Category Tag

Product Details

Pre-Made Murlentamab biosimilar, Whole mAb, Anti-AMHR2 Antibody: Anti-AMHR/MISR2/MISRII/MRII therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Products Name (INN Index)

Pre-Made Murlentamab biosimilar, Whole mAb, Anti-AMHR2 Antibody: Anti-AMHR/MISR2/MISRII/MRII therapeutic antibody

INN Name

Murlentamab

Target

AMHR2

Format

Whole mAb

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2018

Companies

LFB Biotechnologies,GamaMabs Pharma

Conditions Approved

NA

Conditions Active

Colorectal cancer,Gynaecological cancer

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

AMHR2

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide